Crinetics Pharmaceuticals (CRNX) Revenue (2017 - 2026)

Crinetics Pharmaceuticals' Revenue history runs 10 years deep, the most recent figure standing at $10.7 million for Q1 2026.

• In Q1 2026, Revenue rose 2873.41% year-over-year to $10.7 million; the TTM figure through Mar 2026 stood at $18.1 million (up 2277.5% YoY), while the FY2025 annual figure was $7.7 million, up 640.71% from the prior year.
• Revenue for Q1 2026 stood at $10.7 million, up from $6.2 million in the prior quarter.
• The five-year high for Revenue was $10.7 million in Q1 2026, with the low at $143000.0 in Q3 2025.
• The 5-year median for Revenue is $674500.0 (2022), against an average of $2.0 million.
• The sharpest annual moves came in 2024 and 2026: Revenue sank 76.11% in 2024, then soared 2873.41% in 2026.
• Crinetics Pharmaceuticals' Revenue stood at $709000.0 in 2022, then plunged by 51.2% to $346000.0 in 2023, then climbed by 15.32% to $399000.0 in 2024, then surged by 1444.11% to $6.2 million in 2025, then soared by 74.22% to $10.7 million in 2026.
• Business Quant data shows CRNX's Revenue at $10.7 million in Q1 2026, $6.2 million in Q4 2025, and $143000.0 in Q3 2025.